Our aims were to identify 1) risk factors associated with the acquisition of multidrug resistant (MDR, to 22 3 or more classes of antimicrobials) Proteus mirabilis (Pm) isolates responsible for bloodstream 23 infections (BSIs) and 2) the impact on mortality of such infections. Risk factors for acquiring MDR Pm 24
INTRODUCTION 43
The Gram-negative enteric bacterium Proteus mirabilis (Pm) is an important cause of community and 44 health-care-associated infections, including those involving the urinary tract, abdominal cavity, and the 45 bloodstream itself (13, 19, 50) . Like many other members of the family Enterobacteriaceae, P. mirabilis 46 can harbor numerous plasmid-and integron-mediated determinants of antimicrobial resistance (18) . 47
Multi-drug-resistant (MDR) strains of P. mirabilis generally produce extended-spectrum β-lactamases 48 (ESBLs) or the AmpC-type cephalosporinase, rarely carbapenemases, and their prevalence in some 49 settings is relatively high) (8, 10, 12, 13, 25, 31, 39, 41) 50
Over the past decade, the proportion of BSIs caused by Gram-negative bacteria has risen sharply (11, 26, 51 38, 51). Although 1-3% of all BSIs are caused by Pm (11, 26, 38, 51), the incidence of MDR in the 52 strains responsible for these infections is a cause for concern. In general, MDR infections are known to 53 have a significant impact on the prognosis and survival of hospitalized patients (9, 14, 24, 43, 46), but it 54 is unclear whether MDR strains are associated with worse clinical outcomes in P. mirabilis BSIs. 55
Endimiani et al. (13) found that treatment failure and death are likely to occur in ESBL-producing Pm 56
BSIs. Unfortunately, this study was small, including 23 patients and only 9 patients with ESBL-BSIs. 57
However, we can reasonably assume that empirical therapy is even more likely to be inadequate when 58 infections are caused by MDR strains, and this can negatively affect clinical outcomes, particularly in 59 vulnerable, critically ill patients (9, 21, 24, 47). Patients with Pm BSI are often elderly with multiple 60 preexisting conditions, and many are being cared for in nursing homes (11, 47), characteristics which 61 might reduce their ability to tolerate substantial delays in the administration of effective therapy. Better 62 understanding of the factors that favor these infections might help clinicians identify patients who 63 require more attention during the empirical prescription of antimicrobial therapy, and it would also be 64 useful for developing effective strategies to prevent their spread. 65 We investigated a cohort of patients with Pm BSIs to identify the factors that might predict multidrug 66 resistance and the impact of this resistance on mortality. Standards Institute (CLSI) breakpoints and guidelines (7). Multidrug resistance was defined as 132 nonsusceptibility to at least 1 agent in 3 or more of the following antimicrobial classes: oxyimino-133 cephalosporins, β-lactam/β-lactam inhibitor combinations, fluoroquinolones, trimethoprim-134 sulfamethoxazole, or aminoglycosides (27). Restored isolates also underwent PCR amplification of 135 bla TEM , bla SHV , bla CTX-M , bla CMY , bla VIM , bla KPC , bla PER , bla OXA genes and sequencing of both strands of 136 the PCR products, as previously described (10, 17, 41, 43). 137
Statistical analysis. Continuous variables were compared with the Student's t test (normally distributed 138 variables) or the Mann-Whitney U test (non-normally distributed variables). Categorical variables were 139 evaluated using the chi-square or two-tailed Fisher's exact test. Values are expressed as means ± standard 140 deviation (SD) or median (range) (continuous variables) or as percentages of the group they were derived 141 from (categorical variables). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for 142 all associations. Variables emerging from this analysis with a P value of < 0.2 were included at model 143 entry, and a backward stepwise approach was used to identify independent risk factors. The Kaplan-144
Meier method was used for survival analysis. Two-tailed tests were used to determine statistical 145 significance; a P value of < 0.05 was considered significant. Characteristics of P. mirabilis isolates. As shown in Table 1, almost all the Pm isolates were   155 inhibited by meropenem, β-lactam-β-lactam inhibitor combinations, and amikacin. Thirty-six (36.3%) 156
were classified as MDR. They carried the following ESBL genes: bla TEM-52 (n=13; 36.1%); bla TEM-11 157 (n=11; 30.5%); bla TEM-72 (n=10; 27.8%); and in rare cases bla TEM-93 (n = 1) and bla TEM-111 (n = 1). The 158 laboratory database showed that antimicrobial susceptibility findings were reported 38 to 72 hours after 159 index blood culture collection (mean ± SD, 44.6 ± 4.94 hours). 160
Patient characteristics. Table 2 shows the baseline characteristics of the study cohort. In most cases 161 (82/99, 82.8%) Pm BSI onset occurred > 48 hours after admission, and the median (range) pre-BSI-onset 162 hospital stay was 12 (2-140) days. At this time 54.9% (45/82) of the patients were in medical wards, 163 23.2% (19/82) were in ICUs, and 21.9 % (18/82) were in surgical wards. In the remaining 17 cases 164 (17.2%), the BSI was detected at hospital admission, but 11 of these (11.1% of the total cohort) were 165 also classified as HCA infections. Only 6 (6.1% of the total cohort) had BSIs that could be classified as 166
CA. 167
Risk factors for MDR and non-MDR Pm BSIs. 3.87) were independent predictors of infection with a non-MDR Pm strain, and urinary catheterization 173 was significantly associated with both types of infection (MDR -OR 3.89; non-MDR-OR, 2.84) ( Table  174 4). 175
Outcomes. Shortly after index blood culture collection, all patients were started on empiricalaminoglycoside. The remaining patient was initially treated with a regimen that provided no coverage 181 whatsoever for Gram-negative bacteria. 182
In 20 cases, the drugs prescribed were potentially effective but the Pm strain responsible for the infection 183 was resistant to them (a fluoroquinolone in 8 cases, an oxyimino-cephalosporin in 7, gentamicin in 2, 184 trimethoprim-sulfamethoxazole, in 1, and in 2 cases gentamicin plus an oxyimino-cephalosporin analysis confirmed the higher risks of mortality associated with MDR infections (P < 0.001) (Figure 1) . 193
For the 69 patients who were alive at discharge, the median (range) hospital stay after BSI onset was 20 194 In previous studies, bladder catheterization has been independently linked with antibiotic-resistant 234 strains of Enterobactericeae in patients with BSIs, including those that are community-acquired (2, 47), 235
and Endimiani et al. (13) found it to be a significant risk factor for BSI caused by ESBL-positive Pm 236 strains. In our study bladder catheterization was independently associated with Pm BSIs in general, not 237 just those caused by non-MDR strains. Our data confirm that bladder catheterization is an independent 238 risk factor for developing Pm BSI, but it is important to recall that the presence of a bladder catheter may 239 also be an indirect indicator of relatively poor functional status or significant comorbidities. 240
In addition to the infecting pathogen, the severity and source of the infection, underlying diseases, age, 241
and IIAT have all been associated with mortality in patients with BSIs (3, 21, 43). Our multivariate 242 analysis pinpointed 3 independent predictors of death 21 days after BSI onset: presentation with septic 243 shock, infection with a Pm strain that was MDR, and IIAT, the only one that can be modified to reduce 244 mortality. In our cohort, the 21-day mortality rate among patients who received IIAT (53.3%) was 7 245 times higher than that observed in patients who initially received active antibiotics (7.2%), and IIAT is a 246 distinct risk in patients with MDR infections. Indeed, in our series the presence of multidrug resistance 247 increased the probability of IIAT more than 5-fold (OR, 5.53). All of our MDR isolates produced TEM-248 derived ESBLs and showed very similar resistance profiles characterized by low aztreonam MICs (0.5-4 249 mg/L) and moderately high or elevated MICs (≥2) for the oxyimino-cephalosporins, which is consistent 250 with previous reports (13, 25, 43, 49). 251
In 2010 the CLSI (6) lowered the susceptibility breakpoints for certain cephalosporins and for aztreonam 252 relative to Enterobacteriaceae and eliminated its recommendation for ESBL screening and confirmatory 253 tests. When the new breakpoints were applied, all our MDR ESBL-producing strains emerged as 254 resistant to cefotaxime and ceftriaxone, but most were classified as susceptible to ceftazidime (91.6%), It is important to stress that our analysis was retrospective with sample numbers that were relatively 276 small, and it was performed at a single health-care center, so the results are not necessarily applicable to 277 other settings. However, the relationship between inadequate treatment of serious bacterial infections 278 and poor outcome has been consistently demonstrated in other studies (16, (43) (44) (45) . 279
In summary, multidrug resistance has a significant impact on mortality rates in patients with Pm BSI. 280
Delays in the initiation of effective antimicrobial therapy have deleterious effects on clinical outcomes, 281 and efforts should be made to ensure that appropriate therapy is initiated promptly. a Calculated on the basis of chart data relative to the 24 h following BSI onset. When data were missing for one variable, that variable was assigned a value of 0 indicating that it was within normal limits. If more than one variable was missing, the case was excluded from the study.
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